{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:16:19Z","timestamp":1753892179423,"version":"3.41.2"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82260084"],"award-info":[{"award-number":["No. 82260084"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>DNA methylation inhibitors have been approved for the prevention of Acute Myeloid Leukemia (AML), and their safety profile is not fully characterized. This study was aimed at evaluating the adverse drug reactions (ADRs) of DNA methylation inhibitors by analyzing the individual case safety reports (ICSRs) collected in the EudraVigilance (EV) database.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>The EV database managed by the European Medicines Agency was adopted. The standardized medical terminology set MedDRA was utilized. The ICSRs data of DNA methylation inhibitors for the treatment of acute myeloid leukemia originated from the EV database (2005\u20132024). A descriptive exploration of the combined data from EV was undertaken to assess the age, gender of patients, severity and outcome of ADR, event year, geographical origin and the qualification of the reporting source. A comprehensive assessment was made for severe ADR cases. By means of the Reporting Odds Ratio (ROR) and 95% Confidence Interval (CI), a non-proportional analysis was made for MedDRA<jats:sup>\u00ae<\/jats:sup> SOC in DNA methylation inhibitors. Statistical analysis was executed with SPSS version 23.0, and <jats:italic>p<\/jats:italic> &amp;lt; 0.05 was regarded as statistically significant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Result<\/jats:title><jats:p>The study reveals that reports related to AZACITIDINE increased from 2005 to 2023, with a slight decline in 2024, while those for DECITABINE have been on the rise since 2007. ICSRs were associated with a majority of males and individuals aged 65\u201385. Healthcare professionals frequently reported ICSRs related to DNA methylation inhibitors. A significant portion of these ICSRs were serious and completely resolved. The most common ADRs were identified, and certain ADRs had a higher reporting probability with AZACITIDINE (e.g., Febrile neutropenia, Anamia, etc.) and others with DECITABINE (e.g., Myelosuppression, Thrombocytopenia, etc.).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The analysis regarding ADRs of DNA methylation inhibitors was consistent with the literature information disclosed. AZACITIDINE and DECITABINE each have ADRs with a high probability of being reported. Although the study has the advantage of using the database, it is limited by the spontaneous reporting system. Future improvements are needed to accurately evaluate the safety of the drugs.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1527903","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T06:11:47Z","timestamp":1736835107000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["DNA methylation inhibitors adverse reaction characteristic analysis: an analysis based on the European spontaneous adverse event reporting system"],"prefix":"10.3389","volume":"15","author":[{"given":"Xia","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingwang","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongxin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youfu","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11912-020-00964-1","article-title":"Management of acute myeloid leukemia (AML) in older patients","volume":"22","author":"Abdallah","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"B2","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1182\/blood-2009-03-211003","article-title":"Quantitative DNA methylation predicts survival in adult acute myeloid leukemia","volume":"115","author":"Bullinger","year":"2010","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41392-019-0095-0","article-title":"Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials","volume":"4","author":"Cheng","year":"2019","journal-title":"Signal Transduct. Target Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e672","DOI":"10.1016\/S1470-2045(18)30824-6","article-title":"Venetoclax with decitabine or azacitidine for AML","volume":"19","author":"Das","year":"2018","journal-title":"Lancet Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","article-title":"Acute myeloid leukaemia","volume":"401","author":"DiNardo","year":"2023","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/j.biochi.2012.07.025","article-title":"DNA methylation inhibitors in cancer: recent and future approaches","volume":"94","author":"Gros","year":"2012","journal-title":"Biochimie"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/S1470-2045(15)00038-8","article-title":"Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study","volume":"16","author":"Issa","year":"2015","journal-title":"Lancet Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/bjh.19679","article-title":"Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed\/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients","volume":"205","author":"LeBlanc","year":"2024","journal-title":"Br. J. Haematol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1401962","DOI":"10.3389\/fimmu.2024.1401962","article-title":"The epigenetic modification of DNA methylation in neurological diseases","volume":"15","author":"Li","year":"2024","journal-title":"Front. Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3785\/j.issn.1008-9292.2016.07.09","article-title":"Aberrant DNA methylation and its targeted therapy in acute myeloid leukemia","volume":"45","author":"Li","year":"2016","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban."},{"key":"B11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nmeth.3736","article-title":"Genetics: profiling DNA methylation and beyond","volume":"13","author":"Marx","year":"2016","journal-title":"Nat. Methods"},{"key":"B12","doi-asserted-by":"publisher","first-page":"155810","DOI":"10.1016\/j.phymed.2024.155810","article-title":"Unraveling the pathogenesis of myelosuppression and therapeutic potential of natural products","volume":"132","author":"Nian","year":"2024","journal-title":"Phytomedicine"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1001\/jamaoncol.2017.1114","article-title":"Febrile neutropenia","volume":"3","author":"Patel","year":"2017","journal-title":"JAMA Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.3324\/haematol.2013.084160","article-title":"Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms","volume":"98","author":"Perez","year":"2013","journal-title":"Haematologica"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1002\/cncr.33458","article-title":"De novo acute myeloid leukemia: a population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017","volume":"127","author":"Sasaki","year":"2021","journal-title":"Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/j.ctrv.2011.04.013","article-title":"DNA methylation as a pathogenic event and as a therapeutic target in AML","volume":"37","author":"Schoofs","year":"2011","journal-title":"Cancer Treat. Rev."},{"key":"B17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13148-022-01242-6","article-title":"A validation study of potential prognostic DNA methylation biomarkers in patients with acute myeloid leukemia using a custom DNA methylation sequencing panel","volume":"14","author":"Sestakova","year":"2022","journal-title":"Clin. Epigenetics"},{"key":"B18","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","article-title":"Acute myeloid leukaemia","volume":"392","author":"Short","year":"2018","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3390\/ph14070641","article-title":"Hypomethylating chemotherapeutic agents as therapy for myelodysplastic syndromes and prevention of acute myeloid leukemia","volume":"14","author":"Sorrentino","year":"2021","journal-title":"Pharm. (Basel)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/ijc.23607","article-title":"Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine","volume":"123","author":"Stresemann","year":"2008","journal-title":"Int. J. Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.2146\/ajhp040385","article-title":"Azacitidine: a novel agent for myelodysplastic syndromes","volume":"62","author":"Sullivan","year":"2005","journal-title":"Am. J. Health Syst. Pharm."},{"key":"B22","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/bs.acr.2021.03.007","article-title":"DNA methylation inhibitors: retrospective and perspective view","volume":"152","author":"Uddin","year":"2021","journal-title":"Adv. Cancer Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"4576","DOI":"10.3390\/ijms20184576","article-title":"Aberrant DNA methylation in acute myeloid leukemia and its clinical implications","volume":"20","author":"Yang","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1038\/s41590-024-01932-8","article-title":"Tumor editing suppresses innate and adaptive antitumor immunity and is reversed by inhibiting DNA methylation","volume":"25","author":"Zhang","year":"2024","journal-title":"Nat. Immunol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1527903\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T06:11:51Z","timestamp":1736835111000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1527903\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,14]]},"references-count":24,"alternative-id":["10.3389\/fphar.2024.1527903"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1527903","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2025,1,14]]},"article-number":"1527903"}}